CD44: structure, function, and association with the malignant process - PubMed (original) (raw)
Review
CD44: structure, function, and association with the malignant process
D Naor et al. Adv Cancer Res. 1997.
Abstract
CD44 is a ubiquitous multistructural and multifunctional cells surface adhesion molecule involved in cell-cell and cell-matrix interactions. Twenty exons are involved in the genomic organization of this molecule. The first five and the last 5 exons are constant, whereas the 10 exons located between these regions are subjected to alternative splicing, resulting in the generation of a variable region. Differential utilization of the 10 variable region exons, as well as variations in N-glycosylation, O-glycosylation, and glycosaminoglycanation (by heparan sulfate or chondroitin sulfate), generate multiple isoforms (at least 20 are known) of different molecular sizes (85-230 kDa). The smallest CD44 molecule (85-95 kDa), which lacks the entire variable region, is standard CD44 (CD44s). As it is expressed mainly on cells of lymphohematopoietic origin, CD44s is also known as hematopoietic CD44 (CD44H). CD44s is a single-chain molecule composed of a distal extracellular domain (containing, the ligand-binding sites), a membrane-proximal region, a transmembrane-spanning domain, and a cytoplasmic tail. The molecular sequence (with the exception of the membrane-proximal region) displays high interspecies homology. After immunological activation, T lymphocytes and other leukocytes transiently upregulate CD44 isoforms expressing variant exons (designated CD44v). A CD44 isform containing the last 3 exon products of the variable region (CD44V8-10, also known as epithelial CD44 or CD44E), is preferentially expressed on epithelial cells. The longest CD44 isoform expressing in tandem eight exons of the variable region (CD44V3-10) was detected in keratinocytes. Hyaluronic acid (HA), an important component of the extracellular matrix (ECM), is the principal, but by no means the only, ligand of CD44. Other CD44 ligands include the ECM components collagen, fibronectin, laminin, and chondroitin sulfate. Mucosal addressin, serglycin, osteopontin, and the class II invariant chain (Ii) are additional, ECM-unrelated, ligands of the molecule. In many, but not in all cases, CD44 does not bind HA unless it is stimulated by phorbol esters, activated by agonistic anti-CD44 antibody, or deglycosylated (e.g., by tunicamycin). CD44 is a multifunctional receptor involved in cell-cell and cell-ECM interactions, cell traffic, lymph node homing, presentation of chemokines and growth factors to traveling cells, and transmission of growth signals. CD44 also participates in the uptake and intracellular degradation of HA, as well as in transmission of signals mediating hematopoiesis and apoptosis. Many cancer cell types as well as their metastases express high levels of CD44. Whereas some tumors, such as gliomas, exclusively express standard CD44, other neoplasms, including gastrointestinal cancer, bladder cancer, uterine cervical cancer, breast cancer and non-Hodgkin's lymphomas, also express CD44 variants. Hence CD44, particularly its variants, may be used as diagnostic or prognostic markers of at least some human malignant diseases. Furthermore, it has been shown in animal models that injection of reagents interfering with CD44-ligand interaction (e.g., CD44s- or CD44v-specific antibodies) inhibit local tumor growth and metastatic spread. These findings suggest that CD44 may confer a growth advantage on some neoplastic cells and, therefore, could be used as a target for cancer therapy. It is hoped that identification of CD44 variants expressed on cancer but not on normal cells will lead to the development of anti-CD44 reagents restricted to the neoplastic growth.
Similar articles
- CD44 and the adhesion of neoplastic cells.
Rudzki Z, Jothy S. Rudzki Z, et al. Mol Pathol. 1997 Apr;50(2):57-71. doi: 10.1136/mp.50.2.57. Mol Pathol. 1997. PMID: 9231152 Free PMC article. Review. - Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon.
Jackson DG, Bell JI, Dickinson R, Timans J, Shields J, Whittle N. Jackson DG, et al. J Cell Biol. 1995 Feb;128(4):673-85. doi: 10.1083/jcb.128.4.673. J Cell Biol. 1995. PMID: 7532175 Free PMC article. - CD44 isoform-cytoskeleton interaction in oncogenic signaling and tumor progression.
Bourguignon LY, Zhu D, Zhu H. Bourguignon LY, et al. Front Biosci. 1998 Jul 1;3:d637-49. doi: 10.2741/a308. Front Biosci. 1998. PMID: 9634539 Review. - Interaction of CD44 variant isoforms with hyaluronic acid and the cytoskeleton in human prostate cancer cells.
Welsh CF, Zhu D, Bourguignon LY. Welsh CF, et al. J Cell Physiol. 1995 Sep;164(3):605-12. doi: 10.1002/jcp.1041640319. J Cell Physiol. 1995. PMID: 7544357 - A directly spliced exon 10-containing CD44 variant promotes the metastasis and homotypic aggregation of aggressive non-Hodgkin's lymphoma.
Yakushijin Y, Steckel J, Kharbanda S, Hasserjian R, Neuberg D, Jiang W, Anderson I, Shipp MA. Yakushijin Y, et al. Blood. 1998 Jun 1;91(11):4282-91. Blood. 1998. PMID: 9596677
Cited by
- Cancer stem cells (CSCs), cervical CSCs and targeted therapies.
Huang R, Rofstad EK. Huang R, et al. Oncotarget. 2017 May 23;8(21):35351-35367. doi: 10.18632/oncotarget.10169. Oncotarget. 2017. PMID: 27343550 Free PMC article. Review. - CD147 and Ki-67 overexpression confers poor prognosis in squamous cell carcinoma of oral tongue: a tissue microarray study.
Yu YH, Morales J, Feng L, Lee JJ, El-Naggar AK, Vigneswaran N. Yu YH, et al. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 May;119(5):553-65. doi: 10.1016/j.oooo.2014.12.022. Epub 2015 Jan 7. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015. PMID: 25747176 Free PMC article. - CD44a functions as a regulator of p53 signaling, apoptosis and autophagy in the antibacterial immune response.
Cao L, Fang H, Yan D, Wu XM, Zhang J, Chang MX. Cao L, et al. Commun Biol. 2022 Aug 30;5(1):889. doi: 10.1038/s42003-022-03856-1. Commun Biol. 2022. PMID: 36042265 Free PMC article. - Demonstration of a melanoma-specific CD44 alternative splicing pattern that remains qualitatively stable, but shows quantitative changes during tumour progression.
Raso-Barnett L, Banky B, Barbai T, Becsagh P, Timar J, Raso E. Raso-Barnett L, et al. PLoS One. 2013;8(1):e53883. doi: 10.1371/journal.pone.0053883. Epub 2013 Jan 14. PLoS One. 2013. PMID: 23342032 Free PMC article. - Wnt/β-catenin Signaling Inhibitors suppress the Tumor-initiating properties of a CD44+CD133+ subpopulation of Caco-2 cells.
Kim J, Choi KW, Lee J, Lee J, Lee S, Sun R, Kim J. Kim J, et al. Int J Biol Sci. 2021 Apr 12;17(7):1644-1659. doi: 10.7150/ijbs.58612. eCollection 2021. Int J Biol Sci. 2021. PMID: 33994850 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous